Department of Plastic and Reconstructive Surgery, Guangdong Second Provincial General Hospital, 466 Middle Xin Gang Road, Guangzhou City, 510317, Guangdong Province, China.
Department of Medical Cosmetology, Beijing Huaxia Medical Beauty Hospital, Beijing, China.
Aesthetic Plast Surg. 2024 Apr;48(8):1589-1596. doi: 10.1007/s00266-023-03740-1. Epub 2023 Nov 14.
Infraorbital aging develops during the natural aging process. Various treatment options offer unique benefits, accompanied by diverse side effect profiles, and can be synergistically combined to optimize results. This study aimed to evaluate the efficacy of a comprehensive approach involving non-cross-linked hyaluronic acid injection and smooth absorbable PPDO (poly p-dioxanone) thread insertion for infraorbital rejuvenation.
This retrospective case series study enrolled ten female patients with infraorbital aging from March 2022 to April 2023. Clinical outcomes, patient satisfaction, and adverse events were assessed at 1, 3, and 6 months posttreatment.
The median Global Aesthetic Improvement Scale scores evaluated by the operator and blinded evaluator were 1.70 ± 0.42 and 1.80 ± 0.35, respectively, at six months posttreatment. The median Allergan Infraorbital Hollows Scale determined by the operator was 1.15 ± 0.34 at six months posttreatment, whereas the scores evaluated by the blinded evaluator were 1.15 ± 0.53. At six months after treatment, 50% of patients were satisfied, and an additional 40% reported strong satisfaction with the clinical improvement following treatment. No serious adverse events, such as infections, lumps, irregularities, Tyndall effect, hematoma, or skin necrosis, occurred during the treatment period.
The combination of PPDO thread insertion and non-cross-linked hyaluronic acid injection yielded satisfactory and effective clinical outcomes with no occurrence of serious adverse events for infraorbital rejuvenation. We anticipate that this study will contribute to the advancement of novel treatment options for infraorbital aging.
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
眶下老化是自然衰老过程中的一种表现。各种治疗选择都有其独特的优势，同时也伴随着不同的副作用特征，可以协同结合以优化治疗效果。本研究旨在评估一种综合方法的疗效，该方法包括非交联透明质酸注射和光滑可吸收 PPDO（聚对二氧环己酮）线插入，用于眶下年轻化。
这是一项回顾性病例系列研究，纳入了 2022 年 3 月至 2023 年 4 月期间 10 名眶下老化的女性患者。在治疗后 1、3 和 6 个月评估临床结果、患者满意度和不良反应。
治疗后 6 个月时，操作者和盲法评估者评估的平均整体美学改善量表（Global Aesthetic Improvement Scale）评分分别为 1.70 ± 0.42 和 1.80 ± 0.35。操作者评估的 Allergan 眶下凹陷量表（Infraorbital Hollows Scale）中位数为 1.15 ± 0.34，盲法评估者的评分为 1.15 ± 0.53。治疗后 6 个月时，50%的患者满意，另外 40%的患者对治疗后的临床改善表示非常满意。在治疗期间，没有发生严重的不良反应，如感染、肿块、不平整、Tyndall 效应、血肿或皮肤坏死。
PPDO 线插入和非交联透明质酸注射的联合应用为眶下年轻化提供了满意且有效的临床效果，且无严重不良反应发生。我们预计本研究将为眶下老化的新型治疗选择提供参考。
证据等级 IV：本杂志要求作者为每篇文章分配一个证据等级。有关这些循证医学评级的完整描述，请参考目录或在线作者指南 www.springer.com/00266 。
